Evidence map›Paper›PMID 33738697›Full record

ArticleTargeted oncology2021

Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.

Yeonghak Bang, Changhoon Yoo, Sara Lonardi, Hyung-Don Kim, Caterina Vivaldi, Margherita Rimini, Giovanni Luca Frassineti, Sook Ryun Park, Mario Domenico Rizzato, Min-Hee Ryu and 10 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Yeonghak Bang *Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Changhoon Yoo *Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sara LonardiEarly Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Hyung-Don KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Caterina VivaldiDepartment of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Savi 6, 56126, Pisa, Italy.
Margherita RiminiDepartment of Oncology and Hematology, Division of Oncology, University Hospital of Modena, Via del Pozzo 71, Modena, Italy.
Giovanni Luca FrassinetiDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Sook Ryun ParkDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Mario Domenico RizzatoMedical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Min-Hee RyuDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Francesca SalaniDepartment of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Savi 6, 56126, Pisa, Italy.
Ilario Giovanni RapposelliDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Baek-Yeol RyooDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Vittorina ZagonelMedical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Valentina MassaDepartment of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Savi 6, 56126, Pisa, Italy.
Martina ValgiustiDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Valentina BurgioDepartment of Medical Oncology, San Rafaele Scientific Institute IRCCS, Milan, Italy.
Mario Scartozzi *Department of Medical Oncology, University Hospital of Cagliari, Cagliari, Italy.
Stefano CascinuDepartment of Medical Oncology, San Rafaele Scientific Institute IRCCS, Milan, Italy.
Andrea Casadei-GardiniDepartment of Medical Oncology, San Rafaele Scientific Institute IRCCS, Milan, Italy. casadeigardini@gmail.com.ORCID http://orcid.org/0000-0001-6289-7202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33738697

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.